ArticleCase reports in nephrology2025
Successful Management of Relapsing Primary Focal Segmental Glomerulosclerosis With Tacrolimus and Mycophenolate Multitarget Therapy.
Article in Case reports in nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Successful Management of Relapsing Primary Focal Segmental Glomerulosclerosis With Tacrolimus and Mycophenolate Multitarget Therapy.Case reports in nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome, often resistant to corticosteroid therapy. We report a 75-year-old female with relapsing primary FSGS successfully treated with a dual regimen of tacrolimus and mycophenolate mofetil (MMF) without steroids or cyclophosphamide. Following three years of combination therapy, with concurrent renin-angiotensin system and sodium-glucose cotransporter-2 inhibition, the patient achieved sustained remission with proteinuria < 500 mg/day, without complications. This case underscores the potential of tacrolimus and MMF as a steroid-sparing strategy in managing refractory FSGS. Further research is needed to validate this approach in larger patient populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.